Clinical Trials for Liver Cancer

An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)

TrialFetch AI summary: Adults with colorectal liver metastases and insufficient future liver remnant (<30%, or <40% post-chemotherapy), including select patients with intact primaries and resectable/ablatable extrahepatic disease, are randomized to standard portal vein embolization versus combined portal plus hepatic vein embolization to induce FLR hypertrophy prior to hepatectomy. The trial compares rates and speed of achieving resectable FLR and downstream survival and perioperative outcomes.

ClinicalTrials.gov ID: NCT05428735

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)

TrialFetch AI summary: Adults with unresectable/metastatic, GPC3-positive HCC after ≥2 prior systemic therapies receive lymphodepleting cyclophosphamide/fludarabine followed by ECT204, an autologous ARTEMIS AbTCR T-cell therapy targeting glypican-3 designed to retain cytotoxicity with reduced cytokine release versus CAR T cells. Phase 2 includes cohorts of ECT204 at the RP2D with or without regorafenib pre-treatment to assess impact on safety and efficacy.

ClinicalTrials.gov ID: NCT04864054

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

TrialFetch AI summary: First-line trial in adults with unresectable/advanced HCC (BCLC B not LRT-eligible or C; Child-Pugh A; ECOG 0–1; no prior systemic therapy) comparing rilvegostomig (PD-1/TIGIT bispecific) plus bevacizumab with or without tremelimumab (CTLA-4) versus standard atezolizumab (PD-L1) plus bevacizumab. Excludes significant bleeding risk/anticoagulation needs, active autoimmune disease requiring immunosuppression, CNS mets, hepatic encephalopathy, and prior anti-CTLA-4/TIGIT.

ClinicalTrials.gov ID: NCT06921785

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

TrialFetch AI summary: Adults with unresectable/advanced HCC (ECOG 0–1, Child-Pugh A) who progressed on first-line atezolizumab plus bevacizumab are randomized to cabozantinib or lenvatinib with or without atezolizumab. Atezolizumab is an anti–PD-L1 antibody restoring T-cell activity; cabozantinib and lenvatinib are VEGFR-targeting multi-kinase inhibitors.

ClinicalTrials.gov ID: NCT05168163

A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

TrialFetch AI summary: Adults with advanced/metastatic solid tumors and ECOG 0–2, including a cohort with moderate hepatic impairment (bilirubin >1.5×–≤3× ULN), receive sacituzumab govitecan-hziy (Trop-2–targeted ADC delivering SN-38) on Days 1 and 8; dose-escalation (5→7.5→10 mg/kg) is tested in the impaired-liver cohort with a normal-liver comparator at 10 mg/kg. Excludes recent irinotecan, active CNS disease, Gilbert’s syndrome, strong UGT1A1 modulators, and significant liver-related complications in the impaired cohort.

ClinicalTrials.gov ID: NCT04617522

A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

TrialFetch AI summary: For patients ≥12 years with unresectable/metastatic fibrolamellar hepatocellular carcinoma or adults with other solid tumors harboring the DNAJB1‑PRKACA fusion, including checkpoint‑naïve and some checkpoint‑experienced FLC cohorts. Treatment combines an off‑the‑shelf DNAJB1‑PRKACA junction neoepitope peptide vaccine (adjuvanted with TLR1/2 agonist XS15) with nivolumab (PD‑1 inhibitor) and ipilimumab (CTLA‑4 inhibitor) to augment vaccine‑primed T‑cell responses; a re‑enrollment option may use nivolumab plus vaccine if prior CTLA‑4 toxicity.

ClinicalTrials.gov ID: NCT04248569

Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

TrialFetch AI summary: Adults with unresectable, systemic therapy–naïve HCC (ECOG 0–1, Child-Pugh A) receive triplet therapy with zanzalintinib (XL-092; oral multikinase TKI targeting VEGFR2/MET/TAM), durvalumab (PD-L1 inhibitor) every 4 weeks, and a single priming dose of tremelimumab (CTLA-4 inhibitor), with cohorts exploring sequencing (TKI lead-in vs immediate I/O). Excludes prior PD-1/PD-L1/CTLA-4 or MET/VEGFR TKIs, significant autoimmune disease, active viral hepatitis/HIV, and high bleeding risk; mandatory baseline tumor tissue required.

ClinicalTrials.gov ID: NCT06698250

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

TrialFetch AI summary: Adults with unresectable/locally advanced or metastatic HCC who are systemic therapy–naïve (non-fibrolamellar/sarcomatoid/mixed histologies) are randomized to toripalimab (PD‑1 inhibitor) plus bevacizumab with or without casdozokitug, a first‑in‑class anti–IL‑27 monoclonal antibody (p28 subunit) intended to reverse IL‑27–mediated immunosuppression and enhance T/NK cell activity. Excludes patients with significant ascites or uncontrolled effusions; compares two casdozokitug dose levels versus toripalimab/bevacizumab alone.

ClinicalTrials.gov ID: NCT06679985

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

TrialFetch AI summary: Adults with hepatocellular carcinoma receiving SBRT who are at higher risk for post-radiation hepatic decompensation (e.g., ALBI ≥ −1.81, cumulative target ≥4 cm, or Child-Pugh ≥7) receive short-course oral prednisone starting before and during SBRT to reduce hepatic inflammation and radiation-induced liver toxicity. Prednisone is a corticosteroid (glucocorticoid receptor agonist) with anti-inflammatory/immunosuppressive effects; prior liver-directed therapy allowed if recovered.

ClinicalTrials.gov ID: NCT05901519

An Open Label Phase II Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma

TrialFetch AI summary: Adults with untreated, locally advanced/unresectable hepatocellular carcinoma (Child-Pugh A5–A6, ECOG 0–1) receive atezolizumab (PD-L1 inhibitor) plus bevacizumab (anti-VEGF) with the addition of memantine, an oral uncompetitive NMDA receptor antagonist being investigated to enhance antitumor activity. Key exclusions include Child-Pugh B/C, significant infections, recent major cardiovascular events, untreated/symptomatic CNS metastases or varices, prior memantine use, and mixed HCC histologies.

ClinicalTrials.gov ID: NCT06789757